Revenue
No reported data
Definium Therapeutics, Inc. (DFTX)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Research & development | $117.7M | $65.3M | $52.1M | $36.2M | $34.8M | $18.6M |
| Operating expenses | $166.3M | $103.9M | $93.9M | $66.3M | $93.9M | $33.0M |
| Operating income | −$166.3M | −$103.9M | −$93.9M | −$66.3M | −$93.9M | −$33.0M |
| Net income | −$183.8M | −$108.7M | −$95.7M | −$56.8M | −$93.0M | −$33.9M |
| Basic EPSper diluted share | -$2.06 | -$1.54 | -$2.44 | -$1.84 | -$3.40 | -$0.13 |
| Diluted EPSper diluted share | -$2.06 | -$1.54 | -$2.44 | -$1.84 | -$3.40 | -$0.13 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 25, 2026Form 4 · 10b5-1 | Sullivan MarkChief Legal Officer | SellCommon Shares | 13.0K | $45.03 | $585.8K | 320.6K |
| Jun 25, 2026Form 4 · 10b5-1 | Karlin DanielChief Medical Officer | SellCommon Shares | 10.0K | $45.03 | $451.9K | 503.3K |
| Jun 25, 2026Form 4 · 10b5-1 | Roberts BrandiChief Financial Officer | SellCommon Shares | 3.0K | $45.03 | $135.7K | 209.5K |
| Jun 25, 2026Form 4 · 10b5-1 | Barrow RobertChief Executive Officer | SellCommon Shares | 29.2K | $45.03 | $1.32M | 1.10M |
| Jun 25, 2026Form 4 · 10b5-1 | Wiley Matthew T.Chief Commercial Officer | SellCommon Shares | 2.9K | $45.03 | $129.1K | 174.6K |